Immunological response to chimeric antigen receptor T-cell therapy in pediatric relapsed/refractory acute lymphoblastic leukemia: peak of cytokine levels on day 4 post-infusion
Abstract
Chimeric antigen receptor (CAR) T-cell therapy is associated with specific toxicities related to immunological response to the therapy. The aim of the study was to analyze the kinetics of cytokine responses after CAR T-cell infusion and its correlation with observed toxicities. Data from patients treated with CAR T-cell therapy at a single children oncology center in period from 05.2023 to 08.2024 was analyzed. The data included CAR T-cell count in peripheral blood, hematology laboratory data and proinflammatory biomarkers (IL2, IL4, IL6, IL10, IL17A, TNFα, IFNγ, CRP, ferritin) and observed toxicities. Six patients were treated with CD19 CAR-T cell therapy for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). The expansion of CAR-T cells was observed during the first 14 days following infusion, with the peak occurring between days 6 and 12. Cytokine release syndrome was observed in 5 of 6 analyzed cases, mostly during first week after the infusion. An increase plasma concentration of IL2, IL10, and IFNγ was observed on the fourth day after CAR-T cell infusion. Biphasic peaks were detected in the plasma concentrations of I-4 (on 1 and 4 day), IL6 and IL17a (first days after infusion and day 8 and 9). Day 4 post-infusion was characterized by elevated plasma levels of most of the analyzed cytokines and it was timely related to CRS and ICANS. We also observed an immunological response to the infusion itself, along with CAR-T cell expansion.
Keywords: chimeric antigen receptor T-cellCAR T-cellrelapsed/refractory acute lymphoblastic leukemiachildrencytokines
References
- Maude S, Teachey D, Rheingold S, et al. Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL. Journal of Clinical Oncology. 2016; 34(15_suppl): 3011–3011.
- Sheth VS, Gauthier J. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transplant. 2021; 56(3): 552–566.
- Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16): 1507–1517.
- Hughes AD, Teachey DT, Diorio C. Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy. Semin Immunopathol. 2024; 46(3-4): 5.
- Morris EC, Neelapu SS, Giavridis T, et al. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022; 22(2): 85–96.
- Hong R, Hu Y, Huang He. Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction. Front Immunol. 2021; 12: 627764.
- Biery DN, Turicek DP, Diorio C, et al. Need for standardization of cytokine profiling in CAR T cell therapy. Mol Ther. 2024; 32(9): 2979–2983.
- Hayden PJ, Roddie C, Bader P, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022; 33(3): 259–275.
- Willasch AM, Salzmann-Manrique E, Krenn T, et al. Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience. Bone Marrow Transplant. 2017; 52(2): 201–208.
- Bader P, Pötschger U, Dalle JH, et al. IBFM Study Group;, IntReALL Study Group, I-BFM SCT Study Group, EBMT Paediatric Diseases Working Party, EBMT Paediatric Diseases Working Party. Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. J Clin Oncol . 2021; 39(4): 295–307.
- Mirzaei HR, Mirzaei H, Namdar A, et al. Predictive and therapeutic biomarkers in chimeric antigen receptor T-cell therapy: A clinical perspective. J Cell Physiol. 2019; 234(5): 5827–5841.
- Marschollek P, Liszka K, Mielcarek-Siedziuk M, et al. The Kinetics of Inflammation-Related Proteins and Cytokines in Children Undergoing CAR-T Cell Therapy-Are They Biomarkers of Therapy-Related Toxicities? Biomedicines. 2024; 12(7).
- Hombach AA, Heiders J, Foppe M, et al. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology. 2012; 1(4): 458–466.
- Shen D, Song H, Xu X, et al. Chimeric antigen receptor T cell therapy can be administered safely under the real-time monitoring of Th1/Th2 cytokine pattern using the cytometric bead array technology for relapsed and refractory acute lymphoblastic leukemia in children. Pediatr Hematol Oncol. 2020; 37(4): 288–299.
- Manni S, Del Bufalo F, Merli P, et al. Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies. Nat Commun. 2023; 14(1): 3423.
- McNerney KO, DiNofia AM, Teachey DT, et al. Potential Role of IFNγ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy. Blood Cancer Discov. 2022; 3(2): 90–94.
- Schroeder T, Martens T, Fransecky L, et al. Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities. Intensive Care Med. 2024; 50(9): 1459–1469.
- Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood. 2023; 141(20): 2460–2469.
- Shalabi H, Gust J, Taraseviciute A, et al. Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells. Nat Rev Clin Oncol. 2021; 18(6): 363–378.
- Faude S, Wei J, Muralidharan K, et al. Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse. Blood Adv. 2021; 5(8): 2128–2136.